{"name":"Eva Morava-Kozicz","slug":"eva-morava-kozicz","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"AVTX-801","genericName":"AVTX-801","slug":"avtx-801","indication":"Treatment of Methylmalonic acidemia","status":"phase_2"},{"name":"GlcNAc-GlcN","genericName":"GlcNAc-GlcN","slug":"glcnac-glcn","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"AVTX-801","genericName":"AVTX-801","slug":"avtx-801","phase":"phase_2","mechanism":"AVTX-801 is a gene therapy that aims to treat certain genetic disorders by replacing or repairing faulty genes.","indications":["Treatment of Methylmalonic acidemia"],"catalyst":""},{"name":"GlcNAc-GlcN","genericName":"GlcNAc-GlcN","slug":"glcnac-glcn","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":0,"visitCount":7,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}